# Ibrance Real World Insights

> **NCT03159195** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 652 (actual)

## Conditions studied

- Malignant Neoplasm of Breast

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03159195
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-12
- **Primary completion:** 2020-07-23
- **Final completion:** 2021-06-24
- **Target enrollment:** 652 (ACTUAL)
- **Last updated:** 2025-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03159195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03159195, "Ibrance Real World Insights". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03159195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*